No Detail Found!

Medication Usage Evaluation in Patients Prescribed with Ganciclovir in Bone Marrow Transplantation

Author(s)
Kashif Ali Dow College of Pharmacy, Dow University of Health Sciences Karachi, Pakistan
Fakhsheena Anjum Dow College of Pharmacy, Dow University of Health Sciences Karachi, Pakistan
Mehwish Wajdi Federal Urdu University of arts sciences and technology, Karachi, Pakistan
Zubeda Bhutto Institute of Nursing, Dow University of Health Sciences, Karachi, Pakistan
Rida Naseem National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan
Tahir Sultan Shamsi National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan
Abstract
Background: Cytomegalovirus (CMV) is one of the leading risks in bone marrow transplantation for which Ganciclovir is choice of therapy requiring monitoring due to its cytotoxic potential. Study objectives: The aim of this study was to assess the use of Ganciclovir in the management of CMV in hemato-oncologic patients. Methods: The study was designed to assess the usage pattern of Ganciclovir in concordance with the predefined assessment criteria. The medical record of patients was extracted by a senior clinical pharmacist from the specialty of hematology-Oncology in a hospital located in Karachi, Pakistan. Patients' records of 2016-2017 (24 months) were collected both retrospectively and prospectively to review with CMV positive infection; the nurses' performance regarding drug storage, handling, and preparation for administration was also observed. Assessment criteria were developed to evaluate the appropriateness of Ganciclovir use by applying standard treatment guidelines adapted from the Lexicomp drug monograph specifying its usage details, USP 800 (United States Pharmacopeia) and NIOSH Guidelines The collected data were categorized and analyzed by using Statistical Package for Social Sciences software, version 16.0. Results: For this study, 42 cases with CMV positive infection were observed. Out of n= 42 cases, n= 23 (54.76%) had drug interaction with mycophenolate mofetil and n= 1 (2.38%) case had drug interaction with imipenem cilastatin. Ganciclovir was stopped in n= 8 (19.04%) patients due to development of adverse drug reaction (febrile neutropenia). It was observed by the senior clinical pharmacist that neither the pharmacists nor the nurses were aware of protocol for Ganciclovir handling as per standard treatment guidelines. Conclusion: Ganciclovir was inappropriately managed by the Nurses and Pharmacists which can be improved by developing and implementing local guidelines according to standard protocol.
Publication Details
Page(s) 129-132
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 8, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Transplan, Ganciclovir, Cytomegalovirus, Bone Marrow Transplant
0

Citations

0

Downloads

34

Views